Abeona Therapeutics (ABEO)

[wkpeters]

Part 2 of Access C.E.O. Jeff Davis interview.

http://www.accesspharma.com/newsroom/q-a-with-access-pharmaceuticals-ceo-jeffrey-b-davis-part-2-cobalamin-prolindac-and-thiarabine/


Highlights:

Access recently announced an agreement to make an oral formulation of a large drug on the market, which sells close to $1 billion annually in the injectable form, and could be large in an oral form.

The Cobalamin (B-12) technology can also be used to make current drugs more targeted in their application.

With ProLindac, Access simply took the same active drug in Sanofi’s Eloxatin, called DACH platinum, and came up with an innovative delivery mechanism that enables us to deliver more DACH platinum to the patient, in a more tolerable way. It’s a traditional “drug delivery” strategy, using Access proprietary polymer delivery platform.